Want to join the conversation?
Pharma company $SUPN said a sixth patent has been issued by the United States Patent and Trademark Office on May 31 covering Oxtellar XR, a once-daily extended-release oxcarbazepine product. Oxtellar XR is an antiepileptic drug indicated for adjunctive therapy in treating partial seizures in adults and in children 6-17 years of age.
$WBA is yet to receive US anti-trust clearance for its Rite Aid acquisition. The deadline for the deal expires on January 27.
$BMY plunge 7.2%. No credits to the non-acceleration of approval for lung cancer combination treatment.
Well this is big! I don’t know if it’s someone’s monopoly or genuine excitement, but either way, $CSX is up 23% after market closed. I heard some activist investor is going to blow big money into CSX Corp. Anyone mind explaining?